In an exploratory analysis of the EV-302 trial for patients with tissue available for nectin-4 and PD-L1 evaluation, all patients benefited regardless of scores over chemotherapy, but patients with a tumor nectin-4 H-score ≥275 appeared to have a better median PFS and median OS over patients with tumor nectin-4 H-score <275.10 The gene discussed is NECTIN4; the disease is neoplasm.